Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 1918214)

1.

Use of third-generation cephalosporins. Spirochetes.

Luft B, Mariuz P.

Hosp Pract (Off Ed). 1991;26 Suppl 4:34-9; discussion 53-4. Review.

PMID:
1918214
2.

Viscous dynamics of Lyme disease and syphilis spirochetes reveal flagellar torque and drag.

Harman M, Vig DK, Radolf JD, Wolgemuth CW.

Biophys J. 2013 Nov 19;105(10):2273-80. doi: 10.1016/j.bpj.2013.10.004.

3.

THIRD-GENERATION SYPHILIS: DISCUSSION.

Nabarro D.

Br J Vener Dis. 1933 Apr;9(2):110-8. No abstract available.

4.

THIRD-GENERATION SYPHILIS.

Nabarro D.

Br J Vener Dis. 1933 Jan;9(1):1-30. No abstract available.

5.

SOME PROBLEMS ASSOCIATED WITH THE TRANSMISSION OF SYPHILIS TO THE SECOND AND THIRD GENERATION.

Nabarro DN.

Br J Vener Dis. 1927 Jul;3(3):218-43. No abstract available.

6.

A Case of Third-generation Syphilis.

Helliwell CJ.

Br Med J. 1945 Aug 11;2(4414):186. No abstract available.

7.

Third-generation Syphilis.

Elliott A.

Br Med J. 1936 Jun 13;1(3936):1206. No abstract available.

8.

[Borrelia burgdorferi--a unique bacterium].

Brorson Ø.

Tidsskr Nor Laegeforen. 2009 Oct 22;129(20):2114-7. doi: 10.4045/tidsskr.08.0023. Review. Norwegian. No abstract available.

9.

[Lyme borreliosis].

Krause A, Fingerle V.

Z Rheumatol. 2009 May;68(3):239-52; quiz 253-4. doi: 10.1007/s00393-009-0460-4. German.

PMID:
19387665
10.

Biology and neuropathology of dementia in syphilis and Lyme disease.

Miklossy J.

Handb Clin Neurol. 2008;89:825-44. doi: 10.1016/S0072-9752(07)01272-9. No abstract available.

PMID:
18631798
11.

Clinical and therapeutic aspects of dementia in syphilis and Lyme disease.

Nitrini R.

Handb Clin Neurol. 2008;89:819-23. doi: 10.1016/S0072-9752(07)01271-7. No abstract available.

PMID:
18631797
12.

Anti-tumor necrosis factor-alpha activation of Borrelia burgdorferi spirochetes in antibiotic-treated murine Lyme borreliosis: an unproven conclusion.

Wormser GP, Barthold SW, Shapiro ED, Dattwyler RJ, Bakken JS, Steere AC, Bockenstedt LK, Radolf JD.

J Infect Dis. 2007 Dec 15;196(12):1865-6; author reply 1866-7. doi: 10.1086/523826. No abstract available.

13.
14.

Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.

Yrjänäinen H, Hytönen J, Song XY, Oksi J, Hartiala K, Viljanen MK.

J Infect Dis. 2007 May 15;195(10):1489-96. Epub 2007 Apr 6.

15.

[Treatment of Lyme borreliosis secondary and tertiary stages].

Hansmann Y.

Med Mal Infect. 2007 Jul-Aug;37(7-8):479-86. Epub 2007 Mar 23. Review. French.

PMID:
17367972
16.

Lyme disease guidelines--it's time to move forward.

Donta ST.

Clin Infect Dis. 2007 Apr 15;44(8):1134-5; author reply 1137-9. No abstract available.

17.

Current controversies in the management of adult syphilis.

Stoner BP.

Clin Infect Dis. 2007 Apr 1;44 Suppl 3:S130-46. Review.

18.

Persistent joint swelling and Borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment.

Yrjänäinen H, Hytönen J, Söderström KO, Oksi J, Hartiala K, Viljanen MK.

Microbes Infect. 2006 Jul;8(8):2044-51. Epub 2006 May 30.

PMID:
16797205
19.

In vitro activity of eight oral cephalosporins against Borrelia burgdorferi.

Hunfeld KP, Rödel R, Wichelhaus TA.

Int J Antimicrob Agents. 2003 Apr;21(4):313-8.

PMID:
12672576
20.

Cystic forms of Borrelia burgdorferi sensu lato: induction, development, and the role of RpoS.

Murgia R, Piazzetta C, Cinco M.

Wien Klin Wochenschr. 2002 Jul 31;114(13-14):574-9.

PMID:
12422604
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk